1. Home
  2. FIGX vs DERM Comparison

FIGX vs DERM Comparison

Compare FIGX & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FIGX
  • DERM
  • Stock Information
  • Founded
  • FIGX 2025
  • DERM 2014
  • Country
  • FIGX United States
  • DERM United States
  • Employees
  • FIGX N/A
  • DERM N/A
  • Industry
  • FIGX
  • DERM Biotechnology: Pharmaceutical Preparations
  • Sector
  • FIGX
  • DERM Health Care
  • Exchange
  • FIGX Nasdaq
  • DERM Nasdaq
  • Market Cap
  • FIGX 193.9M
  • DERM 190.7M
  • IPO Year
  • FIGX 2025
  • DERM 2021
  • Fundamental
  • Price
  • FIGX $10.01
  • DERM $7.73
  • Analyst Decision
  • FIGX
  • DERM Strong Buy
  • Analyst Count
  • FIGX 0
  • DERM 3
  • Target Price
  • FIGX N/A
  • DERM $12.67
  • AVG Volume (30 Days)
  • FIGX 16.2K
  • DERM 152.6K
  • Earning Date
  • FIGX 01-01-0001
  • DERM 11-07-2025
  • Dividend Yield
  • FIGX N/A
  • DERM N/A
  • EPS Growth
  • FIGX N/A
  • DERM N/A
  • EPS
  • FIGX N/A
  • DERM N/A
  • Revenue
  • FIGX N/A
  • DERM $56,397,000.00
  • Revenue This Year
  • FIGX N/A
  • DERM $26.16
  • Revenue Next Year
  • FIGX N/A
  • DERM $45.27
  • P/E Ratio
  • FIGX N/A
  • DERM N/A
  • Revenue Growth
  • FIGX N/A
  • DERM N/A
  • 52 Week Low
  • FIGX $9.95
  • DERM $3.54
  • 52 Week High
  • FIGX $10.06
  • DERM $8.90
  • Technical
  • Relative Strength Index (RSI)
  • FIGX N/A
  • DERM 55.63
  • Support Level
  • FIGX N/A
  • DERM $7.38
  • Resistance Level
  • FIGX N/A
  • DERM $8.34
  • Average True Range (ATR)
  • FIGX 0.00
  • DERM 0.38
  • MACD
  • FIGX 0.00
  • DERM 0.06
  • Stochastic Oscillator
  • FIGX 0.00
  • DERM 56.65

About FIGX FIGX Capital Acquisition Corp. Class A Ordinary Share

FIGX Capital Acquisition Corp is a blank check company.

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Share on Social Networks: